Michael Piansky, MD
Internal Medicine · Douglasville, GANPI 1023087491
Payments from drug & device makers
Across 253 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$945
- Novo Nordisk$470
- Amgen$429
- Lilly USA, LLC$345
- Pfizer$273
- Boehringer Ingelheim$244
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,307100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $945 |
| Novo Nordisk | 27 | $470 |
| Amgen | 27 | $429 |
| Lilly USA, LLC | 21 | $345 |
| Pfizer | 16 | $273 |
| Boehringer Ingelheim | 13 | $244 |
| AbbVie(2 entities) | 13 | $221 |
| Merck | 15 | $216 |
| Abbott | 8 | $141 |
| Eisai Inc. | 6 | $106 |
| GSK | 6 | $102 |
| Bayer | 4 | $89 |
| Exact Sciences | 6 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Astellas Pharma US Inc | 4 | $64 |
| Phathom Pharmaceuticals, Inc. | 4 | $63 |
| Dexcom, Inc. | 3 | $62 |
| Amarin Pharma, Inc. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Optinose US, Inc. | 1 | $30 |
| Dynavax Technologies Corporation | 1 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$4,320 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 102 | $99,598 |
| OzempicSemaglutide | 62 | $98,327 |
| JanuviaSitagliptin Phosphate | 57 | $58,886 |
| MounjaroTirzepatide | 30 | $53,878 |
| JardianceEmpagliflozin | 60 | $49,858 |
| TrulicityDulaglutide | 33 | $44,445 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $43,740 |
| EliquisApixaban | 31 | $24,826 |
| RybelsusSemaglutide | 11 | $14,238 |
| LinzessLinaclotide | 16 | $13,532 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,670 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $9,495 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $9,063 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $7,047 |
| Novolog FlexpenInsulin Aspart | 19 | $6,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $470 | $112,56573 claims |
| AstraZenecaFarxiga, Symbicort | $945 | $104,066121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $345 | $98,32463 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Jentadueto | $244 | $61,78583 claims |
| MerckJanuvia | $216 | $58,88657 claims |
| PfizerEliquis | $273 | $24,82631 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $102 | $21,73227 claims |
| AbbVieLinzess, Synthroid | $221 | $17,65863 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Douglasville
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.